Showing 2851-2860 of 10578 results for "".
Addressing Itch in Prurigo Nodularis Clinical Trials
https://practicaldermatology.com/programs/dermatology-hub-neuroimmune-network/derm-hub/37170/Raja Sivamani, MD, MS, AP, an integrative dermatologist and Adjunct Associate Professor of Clinical Dermatology at the University of California, Davis, addresses how future prurigo nodularis trials could better address the heterogeneity in disease burden and patient-reported outcomes.Food Allergies and Atopic Dermatitis in the Pediatric Population
https://practicaldermatology.com/programs/dermatology-hub-neuroimmune-network/food-allergies-and-atopic-dermatitis-in-the-pediatric-population/37175/Elizabeth Lippner, MD, MA, Attending Physician in the Division of Allergy and Immunology and Assistant Professor of Pediatrics at Northwestern University Feinberg School of Medicine, discusses potential links between food allergies and pediatric atopic dermatitis, and how to address them.Unmet Needs in Atopic Dermatitis Management
https://practicaldermatology.com/programs/dermatology-hub-neuroimmune-network/unmet-needs-in-atopic-dermatitis-management/37145/Practical Dermatology Chief Medical Editor Neal Bhatia, MD, FAAD, a board-certified dermatologist in San Diego, California, and Director of Clinical Dermatology at Therapeutics Clinical Research, says the most pressing unmet needs in atopic dermatitis management today involve the targets of therapyDermwire TV: 2025 in Review
https://practicaldermatology.com/series/dermwire-tv/dermwire-tv-2025-in-review/54093/Dermwire TV takes a look back at the most popular stories from the Practical Dermatology news and multimedia ecosystem.Effector Cell Response Inhibitors
https://practicaldermatology.com/series/c-suite-chats/effector-cell-response-inhibitors/48960/Excellergy cofounder Alexander Eggel, PhD, and CEO Todd Zavodnick discuss a recent Journal of Allergy and Clinical Immunology article validating the trifunctional mechanism of action of effector cell response inhibitors (ECRIs) for the treatment of allergic diseases, including chronic spontaneous urDermwire TV: Topical Caffeine for Hair Growth, Tapinarof for Pediatric AD
https://practicaldermatology.com/series/dermwire-tv/dermwire-tv-topical-caffeine-for-hair-growth-tapinarof-for-pediatric-ad/48734/This episode highlights studies showing potential for topical caffeine in hair growth in patients with alopecia areata, as well as recent positive results for tapinarof cream 1% for children with AD. Also, Cutera CEO Taylor Harris talks with Practical Dermatology about the evolving needs of today’sNew Devices and Adaptogens
https://practicaldermatology.com/conferences/science-of-skin-summit-2025/tbd/39741/Jacqueline Watchmaker, MD, explores the intersection of medical devices and adaptogenic therapies in skincare. This video was recorded at the Science of Skin Summit in Austin, TX.DermwireTV: FDA Clears Roflumilast, Guselkumab for Pediatric Populations, Plus More
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-fda-clears-roflumilast-guselkumab-for-pediatric-populations-plus-more/39732/This episode highlights two new important pediatric approvals for treatments in both atopic dermatitis and psoriatic disease, also features a clip from a recent YoungMD Connect (YMDC) mentorship session with Dr. Tina Bhutani covering both career paths in both academia and industry.The Battle of Biostimulators: PLLA vs Hyperdilute CaHA
https://practicaldermatology.com/youngmd-connect/on-demand-virtual-sessions/the-battle-of-biostimulators-plla-vs-hyperdilute-caha/39250/Modern Aesthetics executive editor Kay Durairaj, MD, FACS, hosts a workshop describing the differences between two dermal filler options, and how she utilizes both in her practice. YoungMD Connect is an editorially independent platform made possible by industry sponsorships. We would like to thank oIncreased APS Risk for Psoriasis Patients, Plus More
https://practicaldermatology.com/series/dermwire-tv/increased-aps-risk-for-psoriasis-patients-plus-more/39299/This episode highlights research showing increased risk for anti-phospholipid syndrome (APS) in patients with psoriatic disease, as well as research showing increased risks for tuberculosis in patients treated with immunosuppressants. The episode also features a clip from an in-depth discussion arou